期刊
VACCINE
卷 31, 期 -, 页码 D66-D71出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.11.046
关键词
Group B Streptococcus; Vaccine; Perinatal; Pregnancy; Morbidity; Prevention
资金
- Novartis Vaccines Diagnostics
The development of a group B streptococcal (GBS) glycoconjugate vaccine and its upcoming evaluation in a phase 3 trial in pregnant women highlight the importance of defining the anticipated impact of GBS vaccination upon the broad spectrum of GBS-related perinatal morbidity and mortality. We present the specific pregnancy-associated and neonatal conditions attributable, at least in part, to GBS in high and lower income countries. We offer a rationale to support our contention that implementation of GBS glycoconjugate immunization during pregnancy will reduce the global burden of GBS-related morbidity and mortality in pregnant women and their infants. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据